Skip to main content

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

EXTENET
Download
Download is available until [expire_date]
  • Version
  • Download 4
  • File Size 0.00 KB
  • File Count 1
  • Create Date February 10, 2016
  • Last Updated August 25, 2023

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Clinical Care

Leading clinical specialists and surgeons that provide evidence-based treatment

Support

Providing support services
to patients and their families

Research

Consistently running multiple
breast cancer trials

 

©  2024 Breast Cancer Research Centre WA | Privacy Policy and Disclosure Statement